Multifunctional composite nano-enzyme material as well as preparation method and application thereof

By using polydopamine-modified porous barium sulfate nanoparticles loaded with inflammatory regulators, targeted anti-inflammatory treatment is achieved, solving the problem of lack of targeting and side effects of existing IBD treatment methods, significantly improving the accuracy and safety of treatment sex.

CN118987269AActive Publication Date: 2024-11-22ZHEJIANG UNIV

Patent Information

Application Number
CN202411094382.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22
Estimated Expiration
2044-08-09

AI Technical Summary

Technical Problem

The existing IBD treatment methods lack targeting and are difficult to effectively locate the inflammatory colon site, resulting in increased side effects of the drug and poor efficacy, and the condition cannot prevent the worsening.

Method used

Develop a multifunctional composite nanoenzyme material, using polydopamine-modified porous barium sulfate nanoparticles as carriers, loading inflammation regulators such as cerium oxide, dexamethasone and hyaluronic acid, which are negatively charged and can target the inflammatory site. Excess ROS is cleared and macrophage polarization is regulated.

Benefits of technology

Targeted anti-inflammatory treatment is achieved, which significantly relieves inflammation, provides an integrated diagnosis and treatment strategy, which can clearly locate the damaged parts in medical images, improves the accuracy and safety of treatment, and reduces the risk of side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004987433860000011
    Figure HDA0004987433860000011
  • Figure HDA0004987433860000012
    Figure HDA0004987433860000012
  • Figure HDA0004987433860000021
    Figure HDA0004987433860000021
Patent Text Reader

Abstract

The invention discloses a multifunctional composite nano-enzyme material as well as a preparation method and application thereof, and belongs to the field of biomedical materials. According to the composite nano-enzyme material, porous barium sulfate nano-particles modified by polydopamine are used as a carrier, and an inflammation regulator is loaded on the carrier; meanwhile, the composite nano-enzyme material has electronegativity. The multifunctional composite nano-enzyme disclosed by the invention shows an excellent developing characteristic, can clearly locate injured and inflammatory parts in a medical image, and provides accurate information for clinical diagnosis; meanwhile, a remarkable targeted anti-inflammatory effect is achieved. Namely, the multifunctional composite nano-enzyme can effectively relieve inflammation and accurately locate the focus, and through combination of the developing function and anti-inflammatory treatment, an innovative strategy is provided for clinical diagnosis and treatment integration of diseases such as intestinal inflammation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedical materials, and specifically relates to a multifunctional composite nanoenzyme material and a preparation method and application thereof. Background Art

[0002] Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract caused by multiple factors such as environment, genetics, immunity and microorganisms. It includes two subtypes: ulcerative colitis (UC) and Crohn's disease (CD). The prevalence of IBD is increasing year by year. Moreover, as a common and difficult disease, IBD is incurable and will repeatedly cause lesions in the inner layer of the colon and rectum, which will significantly increase the risk of colon cancer in IBD patients. At the same time, because the pathogenesis has not been fully clarified, IBD has become one of the key and difficult points in gastroenterology research.

[0003] At present, small molecule drugs, antibodies and antibiotics are the main treatments for IBD in clinical practice. For example, traditional treatment drugs include 5-aminosalicylic acid, glucocorticoids, immunosuppressants, etc. However, these drugs only relieve clinical symptoms and cannot prevent the disease from worsening. They have poor clinical efficacy and often cause recurrence of the disease. Moreover, since IBD patients need to take medication for a long time, they are prone to a series of complications such as antibiotic resistance and immune response. The difficulty in treating IBD is partly due to the lack of specificity of the treatment. At the same time, most systems rely on delivery through the bloodstream, and few systems actually target the site of the disease, that is, the inflamed colon lesions, which can lead to increased doses and a wider range of systemic exposure, all of which increase the risk of side effects. Therefore, there is an urgent need to develop an innovative targeting strategy that can localize treatment to the inflamed colon site. Summary of the invention

[0004] In view of this, the object of the present invention is to provide a multifunctional composite nanozyme material and its preparation method and application. The multifunctional composite nanozyme material has a unique combination of structure and function, high biocompatibility, negative charge, can target inflammatory sites, and the loaded inflammatory regulator can simultaneously remove excess ROS and regulate macrophage polarization, and can be applied to the synergistic treatment of IBD in the biomedical field. At the same time, the multifunctional composite nanozyme material has both imaging and inflammation targeting, and can be used as a targeting material for integrated diagnosis and treatment.

[0005] In order to achieve the above object, the present invention adopts the following technical solution:

[0006] In the first aspect of the present invention, a multifunctional composite nanozyme material is provided, which uses porous barium sulfate nanoparticles modified with polydopamine as a carrier, and an inflammatory regulator is loaded on the carrier; at the same time, the composite nanozyme material has negative charge.

[0007] In some specific examples of the present invention, the particle size of the composite nanoenzyme material is 50 to 800 nm.

[0008] In some specific examples of the present invention, the inflammatory regulator is one or more of cerium oxide, dexamethasone and hyaluronic acid.

[0009] In another aspect of the present invention, a method for preparing a multifunctional composite nanozyme material is provided, comprising the following steps:

[0010] (1) mixing porous barium sulfate and anhydrous ethanol to form a barium sulfate-anhydrous ethanol dispersion, adding the barium sulfate-anhydrous ethanol dispersion to an alkaline dopamine solution, stirring the mixture to react, and obtaining polydopamine-modified porous barium sulfate nanoparticles;

[0011] (2) The polydopamine-modified porous barium sulfate nanoparticles are mixed with deionized water to form a dispersion, the dispersion is fully stirred and mixed with an inflammatory regulator, and freeze-dried to obtain a multifunctional composite nanozyme material.

[0012] In some specific examples of the present invention, in step (1), the porous barium sulfate is prepared by the following method: barium chloride, ammonium sulfate and polyvinyl alcohol are placed in deionized water, stirred thoroughly, allowed to stand, and then evaporated at high temperature to prepare porous barium sulfate.

[0013] Preferably, the molar ratio of the barium chloride to the ammonium sulfate is 1:(0.75-1.3).

[0014] Preferably, the mass ratio of the barium chloride to polyvinyl alcohol is 1:(0.02-0.04).

[0015] Preferably, the mass ratio of the barium chloride to the deionized water is 1:(15-150).

[0016] Preferably, the temperature of the evaporation at high temperature is 400-800° C., and the evaporation time is 4h-8h.

[0017] In some specific examples of the present invention, in step (1), the alkaline dopamine solution is prepared by the following method: firstly mixing dopamine monomer with deionized water, then adding Tris buffer dropwise to adjust the pH value to 8.5, to obtain an alkaline dopamine solution.

[0018] Preferably, in the alkaline dopamine solution, the concentration of dopamine monomer is 1-5 mg / mL, and more preferably, the concentration of dopamine monomer is 2 mg / mL.

[0019] Preferably, the mass ratio of the dopamine monomer to the porous barium sulfate is 1:1 to 1:10, and the stirring reaction time is 60 to 400 minutes.

[0020] In some specific examples of the present invention, in step (2), the inflammatory regulator is one or more of cerium oxide, dexamethasone and hyaluronic acid.

[0021] Preferably, in step (2), the inflammatory regulators are cerium oxide and dexamethasone.

[0022] Preferably, in step (2), the inflammation regulators are cerium oxide and hyaluronic acid.

[0023] In some specific examples of the present invention, in step (2), the mass ratio of the polydopamine-modified porous barium sulfate nanoparticles to the inflammatory regulator is 1:(0.125-0.75).

[0024] In some specific examples of the present invention, in step (2), the polydopamine-modified porous barium sulfate nanoparticles are mixed with deionized water to form a dispersion, the dispersion is added to a mixed solution formed by cerium nitrate hexahydrate, ethylene glycol and ammonia water, and after being fully stirred and mixed at 80-100° C., freeze-dried to obtain a multifunctional composite nanoenzyme material.

[0025] In some specific examples of the present invention, in step (2), the polydopamine-modified porous barium sulfate nanoparticles are mixed with deionized water to form a dispersion, the dispersion is added to a mixed solution formed by cerium nitrate hexahydrate, ethylene glycol and ammonia water, and after being fully stirred and mixed at 80-100° C., dexamethasone and / or hyaluronic acid are added at room temperature, and after continuing to stir and mix fully, freeze-drying is performed to obtain a multifunctional composite nanoenzyme material.

[0026] Preferably, in step (2), the concentration of the polydopamine-modified porous barium sulfate in the dispersion is 40 mg / mL.

[0027] Preferably, in step (2), the usage ratio of cerium nitrate, ethylene glycol and ammonia water is (0.2-0.4) g: (8-15) mL: (3-6) mL.

[0028] Preferably, in step (2), the stirring and mixing time at 80-100° C. is 60-120 min.

[0029] Preferably, in step (2), the time of stirring and mixing at room temperature is 30 to 300 minutes.

[0030] Preferably, in step (2), the freeze-drying time is 24 to 72 hours.

[0031] Preferably, in step (2), the mass ratio of the polydopamine-modified porous barium sulfate nanoparticles to cerium nitrate hexahydrate is 1:(0.2-0.5).

[0032] Preferably, in step (2), the mass ratio of the polydopamine-modified porous barium sulfate nanoparticles to the dexamethasone and / or hyaluronic acid is 1:(0.2-0.5).

[0033] In another aspect of the present invention, the application of the above-mentioned multifunctional composite nanoenzyme material is also provided, especially the application in the preparation of materials for targeted treatment of intestinal inflammation, and the application in the preparation of integrated diagnosis and treatment drugs.

[0034] Compared with the prior art, the present invention has the following beneficial technical effects:

[0035] (1) In the multifunctional composite nanozyme material of the present invention, the porous barium sulfate nanoparticles modified with polydopamine as a carrier have excellent adsorption properties and strong adhesion properties, and have good stability for the loaded inflammatory regulator. At the same time, the multifunctional composite nanozyme material as a whole has good functionalization ability, that is, it exhibits excellent development properties, and can clearly locate the site of injury and inflammation in medical images, providing accurate information for clinical diagnosis; at the same time, it has a significant targeted anti-inflammatory effect. That is, the multifunctional composite nanozyme of the present invention can effectively relieve inflammation and accurately locate the lesion. By combining the development function with anti-inflammatory treatment, it provides an innovative strategy for the integration of clinical diagnosis and treatment of diseases such as intestinal inflammation.

[0036] (2) The multifunctional composite nanozyme material of the present invention has good biocompatibility and is an efficient and safe composite nanozyme.

[0037] (3) The preparation method of the present invention is simple and easy to implement, and is conducive to promotion and application. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 The X-ray diffraction spectra of the intermediate products, the obtained products and the products obtained in the comparative examples of the present invention are shown in FIG.

[0039] Figure 2 The infrared spectra of the intermediate products, the obtained products and the products obtained in the comparative examples of the present invention are shown in FIG.

[0040] Figure 3 This is a transmission electron microscope photograph of the product obtained in step ① in Example 1 of the present invention.

[0041] Figure 4 This is a transmission electron microscope photograph of the product obtained in step ② in Example 1 of the present invention.

[0042] Figure 5 This is a scanning electron microscope image of the product BPC obtained in Example 1 of the present invention.

[0043] Figure 6 This is a scanning electron microscope image of the product BPCD obtained in Example 2 of the present invention.

[0044] Figure 7 This is a scanning electron microscope image of the product BPCA obtained in Example 3 of the present invention.

[0045] Fig. 8A This is a scanning electron microscope image (partial) of the product BPC obtained in Example 1 of the present invention.

[0046] Figure 8B This is a scanning electron microscope image (partial) of the product BC obtained in Comparative Example 2 of the present invention.

[0047] Fig. 9A This is an X-ray development comparison diagram of the product BPCD obtained in Example 2 of the present invention and the porous barium sulfate obtained in step ①. Fig. 9B The corresponding gray value comparison chart is shown in Figure 2.

[0048] Fig.10 This is a comparison chart of the Zeta potential of the product BPCD obtained in Example 2 of the present invention and the product cerium oxide CeO2 obtained in Comparative Example 1.

[0049] Fig.11 The electron spin resonance spectra of the CAT catalytic activity of the product BPCD obtained in Example 2 of the present invention and the product cerium oxide CeO2 obtained in Comparative Example 1 in hydrogen peroxide are compared.

[0050] Fig.12 The Ce in the product BPCD obtained in Example 2 of the present invention and the product CeO2 obtained in Comparative Example 1 is 3+ and Ce 4+ Comparison of XPS test experimental results.

[0051] Fig.13 The results of the cell activity experiment with different concentrations of the product BPCD obtained in Example 2 of the present invention added thereto are shown.

[0052] Fig.14 The test results of BPCD obtained in Example 4 of the present invention and cerium oxide CeO2 obtained in Comparative Example 1 on ROS scavenging ability are compared.

[0053] Fig.15 The effects of the products obtained from different embodiments of the present invention, as well as porous barium sulfate and pure cerium oxide on the phenotype of macrophages are demonstrated. DETAILED DESCRIPTION

[0054] In order to better illustrate the present invention and facilitate understanding of the technical solution of the present invention, the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments. It should be understood that the following embodiments are only used to illustrate the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.

[0055] In the following examples and comparative examples, the reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased from the market. For example, DMEM high-glucose medium was purchased from Hangzhou Jinuo Biological Co., Ltd., CCK-8 cell activity kit was purchased from Dojindo, Japan, H2DCFDA ROS probe was purchased from MedChemExpress, USA, lipopolysaccharide (LPS) was purchased from Shanghai Biyuntian, APC anti-mouse CD197 (CCR7), anti-mouse CD16 / CD32, FITC anti-mouse CD206 antibodies were all purchased from Thermo Scientific, USA. Polyvinyl alcohol is 1788 type, molecular weight 130.14200. The following room temperature refers to 15-27°C.

[0056] 1. Preparation method

[0057] Example 1 Preparation of BPC

[0058] ① Place 1.7g of barium chloride, 1g of ammonium sulfate and 0.05g of polyvinyl alcohol in 100mL of deionized water and stir thoroughly for 24h, then let stand for another 24h, then evaporate at 600℃ for 4h to remove the polyvinyl alcohol to obtain porous barium sulfate;

[0059] ② Mix 0.2g of dopamine monomer with 100mL of deionized water, and then dropwise add 1mol / L Tris buffer thereto until pH=8.5, to form 100mL of 2mg / mL alkaline dopamine solution; 0.4g of the porous barium sulfate obtained in step ① and 10mL of anhydrous ethanol are mixed to form a barium sulfate-anhydrous ethanol dispersion; the above barium sulfate-anhydrous ethanol dispersion is added to the above alkaline dopamine solution, stirred for 8h, centrifuged, and the obtained solid phase product is washed with deionized water and centrifuged, and the process is repeated three times to obtain polydopamine-modified porous barium sulfate nanoparticles;

[0060] ③ The polydopamine-modified porous barium sulfate nanoparticles obtained in step ② were mixed with deionized water to form a dispersion of polydopamine-modified porous barium sulfate with a concentration of 40 mg / mL. 10 mL of the dispersion was added to a mixed solution formed by 0.252 g of cerium nitrate hexahydrate, 10 mL of ethylene glycol and 3.6 mL of ammonia water, stirred at 90 ° C for 1 h to ensure sufficient mixing, and then freeze-dried for 24 h to obtain a multifunctional composite nanoenzyme material BPC.

[0061] Example 2 Preparation of BPCD

[0062] ① Place 3.3 g of barium chloride, 2 g of ammonium sulfate, and 0.1 g of polyvinyl alcohol in 200 mL of deionized water and stir thoroughly for 24 h, then let stand for another 24 h, and then evaporate at 600 ° C for 8 h to remove the polyvinyl alcohol to prepare porous barium sulfate;

[0063] ② Mix 0.2g of dopamine monomer with 100mL of deionized water, and then dropwise add 1mol / L Tris buffer thereto until pH=8.5, to form 100mL of 2mg / mL alkaline dopamine solution; 0.4g of the porous barium sulfate obtained in step ① and 10mL of anhydrous ethanol are mixed to form a barium sulfate-anhydrous ethanol dispersion; the above barium sulfate-anhydrous ethanol dispersion is added to the above alkaline dopamine solution, stirred for 8h, centrifuged, and the obtained solid phase product is washed with deionized water and centrifuged, and the process is repeated three times to obtain polydopamine-modified porous barium sulfate nanoparticles;

[0064] ③ The polydopamine-modified porous barium sulfate nanoparticles obtained in step ② were mixed with deionized water to form a dispersion of polydopamine-modified porous barium sulfate with a concentration of 40 mg / mL. 10 mL of the dispersion was added to a mixed solution formed by 0.252 g of cerium nitrate hexahydrate, 10 mL of ethylene glycol and 3.6 mL of ammonia water, and stirred at 90 ° C for 1 h to ensure sufficient mixing. Then, 0.2 g of dexamethasone sodium acetate was added at room temperature, and stirring was continued for 3 h, and then freeze-dried for 24 h to obtain a multifunctional composite nanoenzyme material BPCD.

[0065] Example 3 Preparation of BPCA

[0066] ① Place 2.6 g of barium chloride, 1.7 g of ammonium sulfate and 0.08 g of polyvinyl alcohol in 100 mL of deionized water and stir thoroughly for 48 h, then let stand for another 48 h, evaporate at 600 ° C for 4 h to remove the polyvinyl alcohol, and prepare porous barium sulfate;

[0067] ② Mix 0.2g of dopamine monomer with 100mL of deionized water, and then dropwise add 1mol / L Tris buffer thereto until pH=8.5, to form 100mL of 2mg / mL alkaline dopamine solution; 0.4g of the porous barium sulfate obtained in step ① and 10mL of anhydrous ethanol are mixed to form a barium sulfate-anhydrous ethanol dispersion; the above barium sulfate-anhydrous ethanol dispersion is added to the above alkaline dopamine solution, stirred for 8h, centrifuged, and the obtained solid phase product is washed with deionized water and centrifuged, and the process is repeated three times to obtain polydopamine-modified porous barium sulfate nanoparticles;

[0068] ③ The polydopamine-modified porous barium sulfate nanoparticles obtained in step ② were mixed with deionized water to form a dispersion of polydopamine-modified porous barium sulfate with a concentration of 40 mg / mL. 10 mL of the dispersion was added to a mixed solution formed by 0.252 g of cerium nitrate hexahydrate, 10 mL of ethylene glycol and 3.6 mL of ammonia water, and stirred at 90 ° C for 1 h to ensure sufficient mixing. Then, 0.2 g of hyaluronic acid was added at room temperature, and stirring was continued for 3 h, and then freeze-dried for 24 h to obtain a multifunctional composite nanoenzyme material BPCA.

[0069] Example 4 Preparation of BPCD

[0070] ① Place 5.2 g of barium chloride, 3.3 g of ammonium sulfate, and 0.16 g of polyvinyl alcohol in 100 mL of deionized water and stir thoroughly for 24 h, then let stand for 24 h, and then evaporate at 600 ° C for 4 h to remove the polyvinyl alcohol to prepare porous barium sulfate;

[0071] ② Mix 0.04 g of dopamine monomer with 20 mL of deionized water, and then dropwise add 1 mol / L Tris buffer until the pH is 8.5 to form 20 mL of 2 mg / mL alkaline dopamine solution; 0.4 g of the porous barium sulfate obtained in step ① and 10 mL of anhydrous ethanol are mixed to form a barium sulfate-anhydrous ethanol dispersion; the above barium sulfate-anhydrous ethanol dispersion is added to the above alkaline dopamine solution, stirred for 2 h, and centrifuged, and the obtained solid phase product is washed with deionized water and centrifuged, and the mixture is repeated three times to obtain polydopamine-modified porous barium sulfate nanoparticles;

[0072] ③ The polydopamine-modified porous barium sulfate nanoparticles obtained in step ② were mixed with deionized water to form a dispersion of polydopamine-modified porous barium sulfate with a concentration of 40 mg / mL. 10 mL of the dispersion was added to a mixed solution formed by 0.252 g of cerium nitrate hexahydrate, 10 mL of ethylene glycol and 3.6 mL of ammonia water, and stirred at 90 ° C for 1 h to ensure sufficient mixing. Then, 0.2 g of dexamethasone sodium acetate was added at room temperature, and stirring was continued for 3 h, and then freeze-dried for 24 h to obtain a multifunctional composite nanoenzyme material BPCD.

[0073] Example 5 Preparation of BPC

[0074] ① Place 2.5g of barium chloride, 1.3g of ammonium sulfate and 0.08g of polyvinyl alcohol in 300mL of deionized water and stir thoroughly for 48h, then let stand for 24h, then evaporate at 600℃ for 4h to remove the polyvinyl alcohol to prepare porous barium sulfate;

[0075] ② Mix 0.1 g of dopamine monomer with 50 mL of deionized water, and then dropwise add 1 mol / L Tris buffer until the pH is 8.5 to form 50 mL of 2 mg / mL alkaline dopamine solution; 0.4 g of the porous barium sulfate obtained in step ① and 10 mL of anhydrous ethanol are mixed to form a barium sulfate-anhydrous ethanol dispersion; the above barium sulfate-anhydrous ethanol dispersion is added to the above alkaline dopamine solution, stirred for 4 hours, centrifuged, and the obtained solid phase product is washed with deionized water and centrifuged, and the mixture is repeated three times to obtain polydopamine-modified porous barium sulfate nanoparticles;

[0076] ③ The polydopamine-modified porous barium sulfate nanoparticles obtained in step ② were mixed with deionized water to form a dispersion of polydopamine-modified porous barium sulfate with a concentration of 40 mg / mL. 10 mL of the dispersion was added to a mixed solution formed by 0.252 g of cerium nitrate hexahydrate, 10 mL of ethylene glycol and 3.6 mL of ammonia water, stirred at 90 ° C for 1 h to ensure sufficient mixing, and then freeze-dried for 24 h to obtain a multifunctional composite nanoenzyme material BPC.

[0077] Example 6 Preparation of BPCD

[0078] ① Place 5.2 g of barium chloride, 4 g of ammonium sulfate, and 0.2 g of polyvinyl alcohol in 100 mL of deionized water and stir thoroughly for 24 h, then let stand for 24 h, and then evaporate at 600 ° C for 6 h to remove the polyvinyl alcohol to prepare porous barium sulfate;

[0079] ② Mix 0.1 g of dopamine monomer with 50 mL of deionized water, and then dropwise add 1 mol / L Tris buffer until the pH is 8.5 to form 50 mL of 2 mg / mL alkaline dopamine solution; 0.4 g of the porous barium sulfate obtained in step ① and 10 mL of anhydrous ethanol are mixed to form a barium sulfate-anhydrous ethanol dispersion; the above barium sulfate-anhydrous ethanol dispersion is added to the above alkaline dopamine solution, stirred for 4 hours, centrifuged, and the obtained solid phase product is washed with deionized water and centrifuged, and the mixture is repeated three times to obtain polydopamine-modified porous barium sulfate nanoparticles;

[0080] ③ The polydopamine-modified porous barium sulfate nanoparticles obtained in step ② were mixed with deionized water to form a dispersion of polydopamine-modified porous barium sulfate with a concentration of 40 mg / mL. 10 mL of the dispersion was added to a mixed solution formed by 0.252 g of cerium nitrate hexahydrate, 10 mL of ethylene glycol and 3.6 mL of ammonia water, and stirred at 90 ° C for 1 h to ensure sufficient mixing. Then, 0.2 g of dexamethasone sodium acetate was added at room temperature, and stirring was continued for 3 h, and then freeze-dried for 24 h to obtain a multifunctional composite nanoenzyme material BPCD.

[0081] Example 7 Preparation of BPCA

[0082] ① Place 10g of barium chloride, 5g of ammonium sulfate and 0.3g of polyvinyl alcohol in 200mL of deionized water and stir thoroughly for 24h, then let stand for 24h, then evaporate at 600℃ for 8h to remove the polyvinyl alcohol, and prepare porous barium sulfate;

[0083] ② Mix 0.1 g of dopamine monomer with 50 mL of deionized water, and then dropwise add 1 mol / L Tris buffer until the pH is 8.5 to form 50 mL of 2 mg / mL alkaline dopamine solution; 0.4 g of the porous barium sulfate obtained in step ① and 10 mL of anhydrous ethanol are mixed to form a barium sulfate-anhydrous ethanol dispersion; the above barium sulfate-anhydrous ethanol dispersion is added to the above alkaline dopamine solution, stirred for 4 hours, centrifuged, and the obtained solid phase product is washed with deionized water and centrifuged, and the mixture is repeated three times to obtain polydopamine-modified porous barium sulfate nanoparticles;

[0084] ③ The polydopamine-modified porous barium sulfate nanoparticles obtained in step ② were mixed with deionized water to form a dispersion of polydopamine-modified porous barium sulfate with a concentration of 40 mg / mL. 10 mL of the dispersion was added to a mixed solution formed by 0.252 g of cerium nitrate hexahydrate, 10 mL of ethylene glycol and 3.6 mL of ammonia water, and stirred at 90 ° C for 1 h to ensure sufficient mixing. Then, 0.2 g of hyaluronic acid was added at room temperature, and stirring was continued for 3 h, and then freeze-dried for 24 h to obtain a multifunctional composite nanoenzyme material BPCA.

[0085] Comparative Example 1 Preparation of Cerium Oxide

[0086] 0.252 g of cerium nitrate hexahydrate, 10 mL of ethylene glycol and 3.6 mL of aqueous ammonia were mixed, stirred at 90° C. for 1 h, and freeze-dried for 24 h to obtain cerium oxide CeO2.

[0087] Comparative Example 2 Preparation of BC

[0088] ① Place 1.7 g of barium chloride, 1 g of ammonium sulfate, and 0.05 g of polyvinyl alcohol in 100 mL of deionized water and stir thoroughly for 24 hours, then let stand for 24 hours, and then evaporate at 600 ° C for 4 hours to remove the polyvinyl alcohol to prepare porous barium sulfate;

[0089] ② The porous barium sulfate obtained in step ① was mixed with deionized water to form a dispersion of porous barium sulfate with a concentration of 40 mg / mL. 10 mL of the dispersion was added to a mixed solution formed by 0.252 g of cerium nitrate hexahydrate, 10 mL of ethylene glycol and 3.6 mL of ammonia water, stirred at 90° C. for 1 h to ensure sufficient mixing, and then freeze-dried for 24 h to obtain a barium sulfate composite material BC loaded with cerium oxide.

[0090] 2. Composition identification and morphology observation and analysis

[0091] 2.1 X-ray diffraction analysis and infrared analysis were performed on the product BA obtained in step ① of Example 1, the product BP obtained in step ②, the final product BPC obtained in Example 1, the final product BPCD obtained in Example 2, the final product BPCA obtained in Example 3, and Comparative Examples 1 and 2, respectively. The results are as follows: Figure 1 and Figure 2 shown.

[0092] exist Figure 1 In the XRD spectrum, it is shown that:

[0093] Step ① The product BA ( Figure 1 The spectrum corresponding to BaSO4 in the figure) is barium sulfate; the product obtained in reference document 1 ( Figure 1 The spectrum corresponding to CeO2 in the figure is cerium oxide.

[0094] The final product BPC ( Figure 1 In the spectrum corresponding to BPC in the graph, the peaks at 28.5°, 33.1°, 47.5° and 56.3° correspond to the (111)(200)(220)(311) crystal plane peaks of CeO2; the peaks at 25.8°, 31.8°, 33.1° and 42.5° correspond to the (112)(020)(211)(122) crystal plane peaks of barium sulfate. It can be seen that the product BPC is a composite material with barium sulfate and CeO2 crystals, and the crystallinity of CeO2 is good.

[0095] The final product BPCD ( Figure 1In the spectrum corresponding to BPC-D in Figure 2, the peaks at 28.5°, 33.1°, 47.5° and 56.3° correspond to the (111)(200)(220)(311) crystal plane peaks of CeO2; the peaks at 25.8°, 31.8°, 33.1° and 42.5° correspond to the (112)(020)(211)(122) crystal plane peaks of barium sulfate. It can be seen that the product BPCD is a composite material with barium sulfate and CeO2 crystals, and the crystallinity of CeO2 is good.

[0096] The final product BPCA ( Figure 1 In the spectrum corresponding to BPC-A in Figure 1), the peaks at 28.5°, 33.1°, 47.5° and 56.3° correspond to the (111)(200)(220)(311) crystal plane peaks of CeO2; the peaks at 25.8°, 31.8°, 33.1° and 42.5° correspond to the (112)(020)(211)(122) crystal plane peaks of barium sulfate. It can be seen that the product BPCA is a composite material with barium sulfate and CeO2 crystals, and the crystallinity of CeO2 is good.

[0097] The product obtained from comparative document 2 ( Figure 1 The spectrum corresponding to BC in the figure is a composite material of cerium oxide and barium sulfate.

[0098] exist Figure 2 In the FTIR spectrum, the following is shown:

[0099] Step ① The product BA ( Figure 2 The spectrum corresponding to BaSO4 in the figure) is barium sulfate; the product obtained in reference document 1 ( Figure 2 The spectrum corresponding to CeO2 in the figure is cerium oxide.

[0100] Step ② The product BP ( Figure 2 In the spectrum corresponding to BP in -1 , 2930cm -1 , 3390cm -1 The characteristic peaks correspond to the C=O stretching vibration peak, aromatic ring CH stretching vibration peak and NH or OH stretching vibration peak of polydopamine, while the aromatic ring CH stretching vibration peak is not found in the infrared images of the aforementioned BaSO4 and CeO2, which indicates that in the product BP obtained in step ②, polydopamine and barium sulfate are successfully complexed, and the product BP obtained in step ② is barium sulfate modified with polydopamine.

[0101] The final product BPC ( Figure 2 In the spectrum corresponding to BPC, it is located at 1630cm -1 , 2930cm -1 , 3390cm -1The characteristic peaks correspond to the C=O stretching vibration peak, the aromatic ring CH stretching vibration peak and the NH or OH stretching vibration peak of polydopamine, respectively, indicating that in the final product BPC obtained in Example 1, polydopamine and barium sulfate are successfully composited.

[0102] The final product BPCD ( Figure 2 In the spectrum corresponding to BPCD in -1 , 2930cm -1 , 3390cm -1 The characteristic peaks correspond to the C=O stretching vibration peak of polydopamine, the aromatic ring CH stretching vibration peak and the NH or OH stretching vibration peak, located at 1720 cm -1 The C=O stretching vibration peak at 140° belongs to the carboxyl group in dexamethasone, indicating that in the final product BPCD obtained in Example 2, polydopamine and barium sulfate are successfully composited, and dexamethasone is successfully loaded.

[0103] The final product BPCA ( Figure 2 In the spectrum corresponding to BPC-A, the wavelength is 1630 cm -1 , 2930cm -1 , 3390cm -1 The characteristic peaks correspond to the C=O stretching vibration peak, aromatic ring CH stretching vibration peak and NH or OH stretching vibration peak of polydopamine, indicating that: in the final product BPCA obtained in Example 3, polydopamine and barium sulfate are successfully composited; among them, the intensity of the C=O stretching vibration peak increases after loading hyaluronic acid, indicating that hyaluronic acid is successfully loaded.

[0104] 2.2 Morphology observation

[0105] The products obtained in step ① and step ② of Example 1 were analyzed by transmission electron microscopy, and the results are as follows: Figure 3 and Figure 4 As shown. Figure 3 and Figure 4 It can be seen that the barium sulfate product obtained in step ① is a porous particle with a particle size of 250 to 420 nm; the polydopamine-modified barium sulfate particles obtained in step ② have barium sulfate at the center, several holes can be seen, and the transparent boundary layer is a polydopamine layer with a thickness of 5 to 30 nm.

[0106] The morphology of the product BPC obtained in Example 1 was observed under a scanning electron microscope. Figure 5 As shown. Figure 5 It can be seen that the product BPC is nanoparticles, which are evenly dispersed and have a particle size of about 60 to 560 nm.

[0107] The morphology of the product BPCD obtained in Example 2 was observed under a scanning electron microscope. Figure 6 As shown. Figure 6 It can be seen that the product BPCD is nanoparticles, which are evenly dispersed and have a particle size of about 130 to 570 nm.

[0108] The morphology of the product BPCA obtained in Example 3 was observed under a scanning electron microscope. Figure 7 As shown. Figure 7 It can be seen that the product BPCA is nanoparticles, which are evenly dispersed and have a particle size of about 130 to 680 nm.

[0109] The morphology of the product BPC obtained in Example 1 was observed under a scanning electron microscope (30k×). Fig. 8A As shown, it can be seen that cerium oxide is uniformly and massively loaded on the porous barium sulfate modified with polydopamine, indicating that the porous barium sulfate modified with polydopamine has good loading capacity.

[0110] The morphology of the product BC obtained in Comparative Example 2 was observed under a scanning electron microscope (30k×). Figure 8B As shown, it can be seen that the surface cerium oxide loading is small, indicating that pure porous barium sulfate does not have high-density loading performance for cerium oxide.

[0111] In summary, the final product BPC obtained in Example 1 is a porous barium sulfate nanoparticle modified with polydopamine as a carrier, and cerium oxide is loaded on the carrier; the final product BPCD obtained in Example 2 is a porous barium sulfate nanoparticle modified with polydopamine as a carrier, and cerium oxide and dexamethasone are loaded on the carrier; the final product BPCA obtained in Example 3 is a porous barium sulfate nanoparticle modified with polydopamine as a carrier, and cerium oxide and hyaluronic acid are loaded on the carrier. The product BC obtained in Comparative Document 2 is a composite material of porous barium sulfate and cerium oxide.

[0112] 3. Performance test:

[0113] The performance analysis of the products of some embodiments is taken as an example for description.

[0114] 3.1 Analysis of the X-ray imaging ability of the product BPCD obtained in Example 2 and the porous barium sulfate obtained in step ① by CT scanner: BPCD and porous barium sulfate were placed in 1 mL PE tubes (they were at the same height in the PE tubes) respectively, and tested using a high-resolution micro-CT scanner. The CT scanning results are as follows: Fig. 9A The gray value is shown in Fig. 9B As shown, it can be seen that the grayscale value of BPCD is not much different from the grayscale value of porous barium sulfate (BA) obtained in step ①, which means that BPCD basically fully retains the developing ability of porous barium sulfate.

[0115] 3.2 The charge characteristics of the product BPCD obtained in Example 2 and the product CeO2 obtained in Comparative Example 1 were analyzed using a nanometer force potential analyzer. The Zeta potential test results are shown in Fig.10 As shown, it can be seen that compared with the positive charge of cerium oxide, BPCD has a significant negative charge characteristic.

[0116] 3.3 Analysis of OH elimination ability by electron paramagnetic resonance spectroscopy (ESR):

[0117] Take a conical centrifuge tube, add 50 μL of 30wt% hydrogen peroxide and 50 μL of deionized water, then add 50 μL of 0.1g / mL DMPO (5,5-dimethyl-1-pyrroline-N-oxide) aqueous solution to capture for 5 minutes, then take 100 μL of the mixed solution and inject it into the capillary, and then detect hydroxyl radicals (·OH) on an electron paramagnetic resonance spectrometer as a blank control group, recorded as H2O2.

[0118] Take a conical-bottom centrifuge tube, add 50 μL of 30wt% hydrogen peroxide, 50 μL of 100 μg / mL CeO2-water dispersion (CeO2 is cerium oxide prepared in Comparative Example 1), react for 10 minutes, then add 50 μL of 0.1 g / mL DMPO aqueous solution to capture for 5 minutes, then take 100 μL of the mixed solution and inject it into the capillaries, and then detect hydroxyl radicals (·OH) on an electron paramagnetic resonance spectrometer as the control group, recorded as CeO2.

[0119] Take a conical bottom centrifuge tube, add 50 μL of 30wt% hydrogen peroxide and 50 μL of 100 μg / mL BPCD aqueous dispersion (BPCD is the product obtained in Example 2), react for 10 minutes, then add 50 μL of 0.1g / mL DMPO aqueous solution to capture for 5 minutes, then take 100 μL of the mixed solution and inject it into the capillary, and then detect hydroxyl radicals (·OH) on an electron paramagnetic resonance spectrometer as the experimental group, recorded as BPCD.

[0120] ESR test results are as follows Fig.11 As shown. Fig.11 visible:

[0121] DMPO detected a typical 1:2:2:1 ·OH spectrum in the blank control group H2O2, proving the existence of ·OH.

[0122] After adding CeO2 to the same amount of H2O2 as the blank group and reacting for 10 minutes, its EPR spectrum detected lower ·OH, indicating that CeO2 can decompose hydrogen peroxide and has catalase activity.

[0123] After adding an equal amount of BPCD to CeO2 in H2O2 with the same amount as the blank group and reacting for 10 minutes, the EPR spectrum showed that extremely low ·OH was detected, indicating that BPCD can decompose hydrogen peroxide and has stronger catalase activity than pure CeO2.

[0124] 3.4 X-ray photoelectron spectroscopy (XPS) analysis of Ce in the BPCD product obtained in Example 2 and the cerium oxide product obtained in Comparative Example 1 4+ / Ce 3+ Component characteristics. XPS test chart as follows Fig.12 As shown, it can be seen that compared with cerium oxide CeO2, BPCD has higher Ce 3+ Proportion.

[0125] The above performance test results show that the multifunctional composite nanoenzyme material BPCD obtained in Example 2 retains the developing effect of porous barium sulfate, has negative charge characteristics, and has stronger catalase activity than pure CeO2.

[0126] IV. Cell Experiment

[0127] 4.1 CCK-8 cell activity kit was used to detect the effect of different concentrations of nanoparticle materials on the activity of fibroblasts NIH-3T3:

[0128] 5×10 per well 4 NIH-3T3 cells were inoculated at a cell density of 100 μg / mL, and 0.5 mL of DMEM high-glucose medium was added to each well. After culturing for 24 hours at 37°C in an atmosphere of 5% carbon dioxide, it was replaced with 0.5 mL of DMEM high-glucose medium containing different concentrations (5 μg / mL, 50 μg / mL, 100 μg / mL, 500 μg / mL) of the product BPCD nanoparticle material obtained in Example 2. After 24 hours, the old medium was removed, and 50 μL of CCK-8 solution and 500 μL of DMEM high-glucose medium were added to each well. After culturing for 2 hours in a dark environment at 37°C, 120 μL of solution per well was transferred to another 96-well plate, and the absorbance at 450 nm was measured with an ELISA instrument, and the obtained OD value was used to evaluate cell viability.

[0129] At the same time, 5×10 4NIH-3T3 cells were inoculated at a cell density of 100 μg / mL, and 0.5 mL of DMEM high-glucose medium was added to each well. After culturing for 24 hours at 37°C and 5% carbon dioxide, 0.5 mL of new DMEM high-glucose medium was replaced. After 24 hours, the old medium was removed, and 50 μL of CCK-8 solution and 500 μL of DMEM high-glucose medium were added to each well. After culturing for 2 hours at 37°C in the dark, 120 μL of solution was taken from each well and transferred to another 96-well plate. The absorbance at 450 nm was measured with an ELISA reader. The OD value was used to evaluate cell viability and recorded as the blank control group.

[0130] Test results such as Fig.13 As shown, it can be seen that when different concentrations of the multifunctional composite nanozyme material BPCD were added, there was no significant difference in the cell OD value compared with the blank control group (without adding any nanoparticles), indicating that the multifunctional composite nanozyme material BPCD has good biocompatibility.

[0131] 4.2 Flow cytometry was used to analyze the ability of different nanoparticle materials to scavenge ROS:

[0132] RAW264.7 macrophages were cultured at 2×10 5 The cells / well density were inoculated in a 12-well plate, and 24 hours later, they were pretreated with 1 mL of DMEM high-glucose medium containing 100 μg / mL nanoparticle material for 12 hours, and finally treated with 1 mL of DMEM high-glucose medium containing 800 μmol / L H2O2 for 12 hours, and then the cells were stained with the H2DCFDA probe of ROS (in brief, the old medium was removed, PBS was added to rinse the cells twice, and 1 mL of PBS was added for the last time to digest in a 37°C incubator for 5 minutes, the well plate was taken out to flush the completely digested cells, and the cells were collected by centrifugation at 1000 r / min for 3 minutes, PBS was added to wash once, 1 mL of 1 μM H2DCFDA dye working solution was added, and incubated at 37°C for 30 minutes). After that, the cells were centrifuged again at 1000 r / min for 3 minutes, the supernatant was discarded, PBS was added to wash the cells twice by centrifugation, each for 5 minutes, and finally the cells were resuspended with 0.3 mL of PBS and detected by flow cytometry. When the nanoparticle material is CeO2 prepared in Comparative Example 1, it is recorded as CeO2+H2O2; when the nanoparticle material is BPCD obtained in Example 4, it is recorded as BPCD+H2O 2。

[0133] At the same time, a positive control was provided: RAW264.7 macrophages were cultured at 2×10 5The cells / well density was inoculated in a 12-well plate, and 24 hours later, they were pretreated with 1 mL of DMEM high-glucose medium for 12 hours, and finally treated with 1 mL of DMEM high-glucose medium containing 800 μmol / L H2O2 for 12 hours, and then the cells were stained with the H2DCFDA probe of ROS (in brief, the old medium was removed, PBS was added to rinse the cells twice, and 1 mL of PBS was added for the last time to digest in a 37°C incubator for 5 minutes, the well plate was taken out to flush the completely digested cells, and the cells were collected by centrifugation at 1000 r / min for 3 minutes, PBS was added to wash once, 1 mL of 1 μM H2DCFDA dye working solution was added, and incubated at 37°C for 30 minutes). After that, the cells were centrifuged again at 1000 r / min for 3 minutes, the supernatant was discarded, PBS was added to wash the cells twice by centrifugation, each for 5 minutes, and finally the cells were resuspended with 0.3 mL of PBS and detected by flow cytometry, which was recorded as the positive control group H2O 2。

[0134] At the same time, a blank control was also provided: RAW264.7 macrophages were cultured at 2×10 5 The cells / well density was inoculated in a 12-well plate, and 24 hours later, 1 mL of DMEM high-glucose medium was used for pretreatment for 12 hours, and finally 1 mL of DMEM high-glucose medium was used for treatment for 12 hours, and then the cells were stained with the H2DCFDA probe of ROS (in short, the old medium was removed, PBS was added to rinse the cells twice, and 1 mL of PBS was added for the last time to digest in a 37°C incubator for 5 minutes, the well plate was taken out to flush the completely digested cells, and the cells were collected by centrifugation at 1000 r / min for 3 minutes, PBS was added to wash once, 1 mL of 1 μM H2DCFDA dye working solution was added, and incubated at 37°C for 30 minutes). After that, the cells were centrifuged again at 1000 r / min for 3 minutes, the supernatant was discarded, PBS was added to wash the cells twice by centrifugation, each for 5 minutes, and finally the cells were resuspended with 0.3 mL of PBS, and then detected by flow cytometry, which was recorded as the blank control group CTR.

[0135] Test results such as Fig.14 As shown, compared with the blank control group CTR, obvious ROS can be detected in the cells treated with H2O2 in the positive control group H2O2, and the cells have the highest ROS average fluorescence intensity; in the CeO2+H2O2 group, the cells are first pretreated with CeO2 obtained in Comparative Example 1, and then treated with an equal amount of H2O2, and the ROS average fluorescence intensity is significantly reduced, indicating that CeO2 has good biological ROS decomposition characteristics; in the BPCD+H2O2 group, the cells are pretreated with the product BPCD obtained in Example 4, and then treated with an equal amount of H2O2, and the lowest ROS average fluorescence intensity is detected, indicating that: compared with CeO2, BPCD has a better ability to scavenge ROS in organisms.

[0136] 4.3 Analysis of the effects of different nanomaterials on macrophage phenotype using macrophage polarization phenotype induction experiment

[0137] RAW264.7 macrophages were cultured at 2×10 5 The cells / well density was inoculated in a 12-well plate, 1 mL of DMEM high-glucose medium was added and cultured for 24 h, then, 1 mL of high-glucose medium containing 2 μg / mL lipopolysaccharide (LPS) was used to stimulate for 12 h, and the cells were converted into M1 macrophages. The medium was removed, and the obtained M1 macrophages were co-incubated with 1 mL of DMEM high-glucose medium containing 100 μg / mL nanomaterials for 12 h, and the phenotypes of M1 (iNOS) and M2 (CD206) macrophages were detected by flow cytometry. Wherein, when the nanomaterial is the porous barium sulfate prepared in step 1, it is recorded as BA+LPS; when the nanomaterial is CeO2 prepared in comparative example 1, it is recorded as Ce+LPS; when the nanomaterial is the product BPC obtained in Example 5, it is recorded as BPC+LPS; when the nanomaterial is the product BPCD obtained in Example 6, it is recorded as BPCD+LPS; when the nanomaterial is the product BPCA obtained in Example 7, it is recorded as BPCA+LPS.

[0138] At the same time, a blank control was also provided: RAW264.7 macrophages were cultured at 2×10 5 The cells / well density was inoculated in a 12-well plate, and 1 mL of DMEM high-glucose medium was added to culture for 24 h. Then, a new 1 mL of DMEM high-glucose medium was added as a blank control (CTR) and the cells were cultured for another 24 h. The phenotypes of M1 (iNOS) and M2 (CD206) macrophages were detected by flow cytometry.

[0139] RAW264.7 macrophages were cultured at 2×10 5 The cells were seeded in a 12-well plate at a density of 1 cell / well, and 1 mL of DEME high-glucose medium was added for 24 h. Then, they were stimulated for 12 h by 1 mL of DMEM high-glucose medium containing 2 μg / mL lipopolysaccharide (LPS) as an LPS control. The phenotypes of M1 (iNOS) and M2 (CD206) macrophages were detected by flow cytometry.

[0140] The phenotypes of M1 (iNOS) and M2 (CD206) macrophages were detected by flow cytometry as follows:

[0141] The old culture medium was removed, and the cells were rinsed twice with PBS. 1 mL of PBS was added to each well and digested at 37°C for 5 min. The digested cells were washed down and centrifuged at 1000 r / min for 3 min. The supernatant was removed, and 1 μg / μL of anti-mouse CD16 / CD32 antibody was added to each tube of cells for blocking at room temperature for 10 min. The cells were centrifuged again at 1000 r / min for 3 min, and 0.5 mL of PBS was added for washing twice. 0.5 mL of 1 μg / mL APC anti-mouse CD197 (CCR7) and 1 μg / mL FITC anti-mouse CD206 antibodies were added and incubated at 37°C in the dark for 30 min. The supernatant was discarded after centrifugation, and 0.5 mL of PBS was added for centrifugation to wash the cells twice, each for 5 minutes. Finally, the cells were resuspended with 0.3 mL of PBS and detected by flow cytometry.

[0142] Test results such as Fig.15 As shown, the ordinate represents the ratio of the mean fluorescence intensity of M2 and M1 macrophages, and the abscissa represents the groups.

[0143] In the LPS group, after LPS stimulation, the ratio of the mean fluorescence intensity of M2 to M1 macrophages represented by the ordinate was lower than that of the blank control CTR group, indicating that the phenotype of macrophages in this group was mostly M1 type;

[0144] In the BA+LPS group or Ce+LPS group, after LPS stimulation, the M2 phenotype of macrophages continued to be treated with BA or CeO2, and there was no significant change, which was similar to that in the LPS group, indicating that BA or cerium oxide had little effect on the phenotype of macrophages;

[0145] In the BPC group, after LPS stimulation and then BPC treatment, the M2 phenotype of macrophages increased, indicating that BPC has the ability to induce anti-inflammatory polarization of macrophages;

[0146] Similarly, in the BPCD group, after LPS stimulation and then BPCD treatment, the M2 phenotype of macrophages increased significantly, indicating that BPCD has a significant ability to induce anti-inflammatory polarization of macrophages;

[0147] Similarly, in the BPCA group, after LPS stimulation and then BPCA treatment, the M2 phenotype of macrophages increased significantly, indicating that BPCA has a significant ability to induce anti-inflammatory polarization of macrophages.

[0148] It can be seen that porous barium sulfate and pure cerium oxide alone do not have the ability to induce anti-inflammatory polarization of macrophages, while the products BPC / BPCD / BPCA obtained in each embodiment have the ability to induce anti-inflammatory polarization of macrophages, especially BPCD has the strongest ability to induce anti-inflammatory polarization of macrophages.

[0149] In summary, in the above embodiments, porous barium sulfate nanoparticles are first prepared by solvent evaporation method, and then polydopamine is modified to the surface of barium sulfate nanoparticles by self-assembly method, and then inflammatory regulators are further loaded to obtain multifunctional composite nanoenzyme materials. The multifunctional composite nanoenzyme material of the present invention has a unique structure and functional combination, and uses porous barium sulfate nanoparticles modified by polydopamine as a carrier, which not only has high specific surface area and excellent adsorption performance, but also has good biocompatibility and strong adhesion characteristics, so as to have good stability and functionalization ability for the loaded inflammatory regulator. The composite nanoenzyme material presents negative charge, can effectively target the inflammatory site, and enhance its retention time in the inflammatory area by electrostatic interaction; moreover, the composite nanoenzyme material has a variety of inflammation relief mechanisms: on the one hand, it can remove excessive reactive oxygen (ROS), reduce oxidative stress damage to tissues, and relieve inflammation; on the other hand, by inducing the polarization of macrophages, it is promoted to change to an anti-inflammatory phenotype, further inhibiting the inflammatory response, removing excessive reactive oxygen and inducing the synergistic effect of macrophage polarization to relieve inflammation, significantly improving its anti-inflammatory effect, and can be applied to the synergistic treatment of IBD in the biomedical field. In addition, the composite nanozyme material has high biocompatibility and still retains the development properties of barium sulfate, which can safely and efficiently locate the damaged area. Therefore, this multifunctional composite nanozyme has both development and inflammation targeting, and can be used as an integrated diagnosis and treatment targeting material, providing an integrated diagnosis and treatment application strategy for diseases such as intestinal inflammation.

[0150] It can be seen that the purpose of the present invention has been completely and effectively achieved. The functional and structural principles of the present invention have been demonstrated and explained in the embodiments. Without departing from the principles, the implementation methods can be modified arbitrarily. Therefore, the present invention includes all modified implementation methods based on the spirit and scope of the claims.

Claims

1. A multifunctional composite nanozyme material, characterized in that: The composite nanozyme material uses porous barium sulfate nanoparticles modified with polydopamine as a carrier, and an inflammatory regulator is loaded on the carrier; meanwhile, the composite nanozyme material has negative charge.

2. The multifunctional composite nanoenzyme material according to claim 1, characterized in that: The particle size of the composite nanoenzyme material is 50 to 800 nm.

3. The multifunctional composite nanoenzyme material according to claim 1, characterized in that: The inflammation regulator is one or more of cerium oxide, dexamethasone and hyaluronic acid.

4. The method for preparing the multifunctional composite nanoenzyme material according to any one of claims 1 to 3, comprising the following steps: (1) mixing porous barium sulfate and anhydrous ethanol to form a barium sulfate-anhydrous ethanol dispersion, adding the barium sulfate-anhydrous ethanol dispersion to an alkaline dopamine solution, stirring the mixture to react, and centrifuging to obtain polydopamine-modified porous barium sulfate nanoparticles; (2) The polydopamine-modified porous barium sulfate nanoparticles are mixed with deionized water to form a dispersion, the dispersion is fully stirred and mixed with an inflammatory regulator, and freeze-dried to obtain a multifunctional composite nanozyme material.

5. The method according to claim 4, characterized in that In step (1), the alkaline dopamine solution is prepared by the following method: firstly, dopamine monomer is mixed with deionized water, and then Tris buffer is added dropwise to adjust the pH value to 8.5 to obtain an alkaline dopamine solution.

6. The method according to claim 4, characterized in that In step (1), the mass ratio of dopamine monomer in the alkaline dopamine solution to porous barium sulfate in the barium sulfate-anhydrous ethanol dispersion is 1:1 to 1:10, and the stirring reaction time is 60 to 400 minutes.

7. The method according to claim 4, characterized in that In step (2), the mass ratio of the polydopamine-modified porous barium sulfate nanoparticles to the inflammatory regulator is 1:(0.125-0.75).

8. The method according to claim 4, characterized in that In step (2), the polydopamine-modified porous barium sulfate nanoparticles are mixed with deionized water to form a dispersion, and the dispersion is added to a mixed solution formed by cerium nitrate hexahydrate, ethylene glycol and ammonia water. After being fully stirred and mixed at 80-100° C., the mixture is freeze-dried to obtain a multifunctional composite nanoenzyme material.

9. The method according to claim 4, characterized in that In step (2), the polydopamine-modified porous barium sulfate nanoparticles are mixed with deionized water to form a dispersion, the dispersion is added to a mixed solution formed by cerium nitrate hexahydrate, ethylene glycol and ammonia water, and after being fully stirred and mixed at 80-100° C., dexamethasone and / or hyaluronic acid are added at room temperature, and after continuing to be fully stirred and mixed, freeze-dried to obtain a multifunctional composite nanoenzyme material.

10. Use of the multifunctional composite nanoenzyme material according to any one of claims 1 to 3.

Citation Information

Patent Citations

  • Medicine for inflammatory bowel diseases and preparation method and application of medicine

    CN111773243A

  • Hydrogel and preparation method thereof, and application of hydrogel in preparation of antioxidant X-ray / CT visual digestive tract contrast agent

    CN116983438A

Cited By

  • Targeted drug delivery platform based on mesoporous cerium oxide nanoparticles as well as preparation method and application of targeted drug delivery platform

    CN120078725A